R. O’Connor-Semmes

发表

Aging and Exercise Creatine ( methyl -d 3 ) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA

E. Ravussin, W. Cefalu, Ram R Miller, 2017 .

First‐in‐Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

A. Verticelli, K. Hacquoil, P. Gorycki, 2021, Clinical pharmacology in drug development.

First‐in‐Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

A. Verticelli, K. Hacquoil, S. Shakib, 2018, Clinical pharmacology in drug development.

Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes

W. Wilkison, R. Dobbins, A. Sykes, 2015, Diabetes, obesity & metabolism.

Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.

A. Zinsmeister, M. Camilleri, D. Burton, 2004, American journal of physiology. Gastrointestinal and liver physiology.

Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans.

E. Ravussin, W. Evans, W. Cefalu, 2014, Journal of applied physiology.

Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine.

I. M. Davis, K. Koch, Y. Yin, 1998, Journal of pharmaceutical sciences.

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

S. Mudaliar, R. Henry, D. Armstrong, 2012, Diabetes Care.

Effect of ranitidine on the pharmacokinetics of triazolam and α‐hydroxytriazolam in both young (19‐60 years) and older (61‐78 years) people

D. Williams, K. Kersey, K. Koch, 2001 .

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors

A. Drilon, B. Hug, G. Ganji, 2021, The oncologist.

short-term creatine monohydrate supplementation content in skeletal muscle of young men following Global and targeted gene expression and protein

E. Ravussin, S. Melov, W. Evans, 2015 .

Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers

Megan McLaughlin, M. Sanghvi, Megan M. McLaughlin, 2021, Drug Metabolism and Disposition.

Use of the InteliSite® Capsule to Study Ranitidine Absorption from Various Sites Within the Human Intestinal Tract

Alan F. Parr, William D. Heizer, Kim L. R. Brouwer, 1998, Pharmaceutical Research.

Creatine ( methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA.

E. Ravussin, W. Cefalu, Ram R Miller, 2018, Journal of applied physiology.

Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

S. Murray, D. Nunez, M. Kipnes, 2010, Journal of clinical pharmacology.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

W. Wilkison, B. Cheatham, R. Dobbins, 2021, BMC pharmacology & toxicology.

Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment

W. Wilkison, B. Cheatham, R. Dobbins, 2015, Drug Metabolism and Disposition.

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

J. Polli, R. Dobbins, A. Kapur, 2013, BMC Pharmacology and Toxicology.

Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes

W. Wilkison, R. Dobbins, A. Sykes, 2015, Diabetes, obesity & metabolism.

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

C. Kapitza, G. Golor, R. Dobbins, 2012, Diabetes, obesity & metabolism.

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance and Ketoconazole Interaction Studies.

J. Polli, J. Humphreys, R. Dobbins, 2012 .

GSK2374697, a Novel Albumin‐Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin‐4: First Study in Humans—PK/PD and Safety

D. Nunez, R. O'Connor‐Semmes, R. Hodge, 2014, Clinical pharmacology and therapeutics.

GSK2374697, a long duration glucagon‐like peptide‐1 (GLP‐1) receptor agonist, reduces postprandial circulating endogenous total GLP‐1 and peptide YY in healthy subjects

D. Nunez, R. Hodge, J. Lin, 2015, Diabetes, obesity & metabolism.

Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people.

K. Kersey, R. O’Connor-Semmes, D. H. Williams, 2001, Clinical pharmacology and therapeutics.

Regional gastrointestinal delivery of remogliflozin etabonate in humans

R. Dobbins, R. O'Connor‐Semmes, E. Hussey, 2013, Biopharmaceutics & drug disposition.